[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581295":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Affiliated Hospital of Nantong University","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients treated with hydromorphone and midazolam",null,[12],"Other: no-intervention",{"label":14,"type":10,"description":10,"interventionNames":15},"Patients treated with remifentanil and midazolam",[12],[17],{"type":6,"name":18,"description":18,"armGroupLabels":19,"otherNames":10},"no-intervention",[9,14],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Xiaoyu Yuan","CONTACT","13390940060","yxy11238@163.com",[27],{"facility":28,"status":10,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Emergency Department of Affiliated Hospital of Nantong University","Nantong","Jiangsu","226000","China","CN",{"type":35,"coordinates":36},"Point",[37,38],120.87472,32.03028,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100581295","clinical-study-on-the-efficacy-and-safety-of-hydromorphone-for-icu-analgesia-100581295",false,"NCT06848452","Clinical Study on the Efficacy and Safety of Hydromorphone for ICU Analgesia","Inclusion Criteria:\n\n* Age ≥18 years and ≤75 years;\n* For patients requiring sedation and analgesia in ICU, invasive mechanical ventilation time is expected to be ≥24 hours;\n* Obtain informed consent from patients or family members.\n\nExclusion Criteria:\n\n* Under 18 years of age, or over 75 years of age;\n* pregnancy or breastfeeding;\n* Known or suspected allergy to opioids (e.g., fentanyl, remifentanil, hydromorphone), butorphanol, midazolam.\n* General anesthesia surgery within 48 hours;\n* Acute bronchial asthma.\n* Acute intestinal obstruction.\n* General anesthesia surgery within 48 hours;\n* ECG QT interval: male \\>450 mm seconds, female \\>470 ms.\n* Failure to obtain informed consent or authorization;\n* Participate in other exploratory clinical trials within 6 months prior to screening;\n* Severe hemodynamic instability (requires epinephrine greater than 0.5ug\u002Fkg\u002Fmin to maintain MAP\\>65mmHg, or malignant arrhythmias frequently occur)\n* Use of monoamine oxidase inhibitors.\n* Chronic pain requires long-term analgesics (\\>3 months).\n* Severe, pre-existing substantial liver disease with clinically significant portal hypertension, Child-Pugh grade C cirrhosis, or acute liver failure;\n* Patients with acute and chronic renal insufficiency requiring dialysis treatment;\n* Severe craniocerebral injury, brain tumor, increased intracranial pressure, cerebrovascular accident, coma, epileptic status, etc.\n* Patients with a history of alcohol or drug abuse;\n* Any condition that prevents the correct assessment of cognitive function, such as speech and sensory disorders or mental disorders (language difficulties or organic mental dysfunction);\n* any other conditions which the investigator considers inappropriate for registration.","ALL","18 Years","75 Years",{"count":54,"type":55},300,"ESTIMATED","OBSERVATIONAL","This study is a prospective, single-center clinical study to evaluate the advantages, extensibility and safety of hydromorphone as an analgesic drug in ICU, and to compare it with remifentanil, a traditional sedative drug. These conclusions can guide us to understand the characteristics of analgesic drugs, carry out appropriate pain management, improve the status of ICU patients, and improve the quality of life of patients.",[59,60],"Analgesia","ICU Patients Requiring Invasive Mechanical Ventilation",[62,63,64,65,66,67],"ICU","hydromorphone","analgesia","remifentanil","sedation","respirator support","NOT_YET_RECRUITING","2025-03-12",{"date":71,"type":72},"2025-03-14","ACTUAL",{"date":74,"type":55},"2025-03",{"date":76,"type":55},"2027-12-31",{"name":5,"class":6},1]